Stifel analyst Annabel Samimy lowered the price target on Reata Pharmaceuticals (NASDAQ: RETA) to $75.00 (from $240.00) while maintaining a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE